Research Progress on the Inhibition of Glioma Invasion and Migration by Cannabidiol Nanoformulations Based on Modulation of the GADD45/CDC2 Signaling Axis

Abstract

Glioma, the most common malignant tumor of the central nervous system, significantly impacts patient treatment outcomes and survival rates due to its highly invasive and migratory nature. Consequently, exploring effective therapeutic strategies represents a critical focus in current oncology research. In recent years, cannabidiol (CBD) has garnered widespread attention for its unique anti-tumor properties. However, its poor water solubility and low bioavailability limit its clinical application. The application of nanotechnology offers new possibilities for enhancing the delivery and efficacy of CBD.This review summarizes the latest research progress on CBD-based nanoformulations targeting the GADD45/CDC2 signaling axis to inhibit glioma invasion and migration. It highlights the mechanistic role of the GADD45/CDC2 axis in glioma progression and elucidates how CBD nanoformulations suppress tumor growth and metastasis by modulating this pathway. Furthermore, the article discusses the current limitations in the field and outlines future research directions, aiming to provide new insights and approaches for glioma treatment.